Reported Earnings • Aug 14
Second quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2026 results: US$2.32 loss per share. Revenue: US$33.4m (down 12% from 2Q 2025). Net loss: US$67.0m (loss widened 80% from 2Q 2025). Revenue exceeded analyst estimates by 3.8%. Earnings per share (EPS) missed analyst estimates by 63%. Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in the US. Announcement • Aug 13
Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full-Year of 2026 Karyopharm Therapeutics Inc. reaffirmed Earnings Guidance for the Full-Year of 2026. Based on its current operating plans, Karyopharm expects the following for full year 2026: Total revenue to be in the range of $130 million to $150 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners. Announcement • Aug 10
Karyopharm Therapeutics Inc. to Report Q2, 2026 Results on Aug 13, 2026 Karyopharm Therapeutics Inc. announced that they will report Q2, 2026 results Pre-Market on Aug 13, 2026 New Risk • Aug 04
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$44.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-US$266m). Shareholders have been substantially diluted in the past year (162% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$64m net loss in 3 years). Market cap is less than US$100m (US$44.6m market cap). Price Target Changed • Jul 22
Price target increased by 12% to US$14.80 Up from US$13.17, the current price target is an average from 5 analysts. New target price is 88% above last closing price of US$7.87. Stock is up 62% over the past year. The company is forecast to post a net loss per share of US$4.14 next year compared to a net loss per share of US$17.93 last year. Announcement • Jun 03
Karyopharm Therapeutics Presents Results from Phase 3 Sentry Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Karyopharm Therapeutics Inc. presented the results of its Phase 3 SENTRY trial in a late-breaking oral presentation titled: Selinexor plus ruxolitinib in JAK inhibitor-naïve myelofibrosis: Phase 3 SENTRY trial (LBA6500) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The SENTRY results were also published in the peer-reviewed Journal of Clinical Oncology (JCO). The combination of selinexor plus ruxolitinib demonstrated a statistically significant improvement in the co-primary endpoint of spleen volume reduction of 35% or more (SVR35), with rapid, deep and sustained spleen volume reduction seen in the combination arm and a consistent benefit observed across prespecified subgroups. At week 24, SVR35 was achieved in 49.8% of patients randomized to the selinexor combination versus 28.0% of patients randomized to ruxolitinib alone (odds ratio 2.58; 95% CI [1.60 to 4.17]; p). Similar symptom improvement from baseline was observed with the selinexor combination compared to ruxolitinib alone as measured by Abs-TSS at week 24. A mean (95% CI) reduction of 9.9 points (-11.2 to -8.6) was observed in patients randomized to the selinexor combination versus a reduction of 10.9 points (-12.6 to -9.1) in patients randomized to ruxolitinib alone. Symptom reductions were consistent across each of the six domains measured. The adjusted mean difference of 0.97 points (95% CI [-1.07 to 3.02]; p=0.825) in Abs-TSS, a co-primary endpoint, did not meet statistical significance. A promising overall survival signal, a pre-specified secondary endpoint, was observed with the selinexor combination compared to ruxolitinib alone. As of February 20, 2026, 224 (95.3%) patients randomized to the selinexor combination and 106 (89.8%) randomized to ruxolitinib alone were alive. With a median follow-up of 11.6 and 12.6 months, respectively, overall survival favored the selinexor combination with a hazard ratio of 0.43 (95% CI [0.19 to 1.00]; nominal one-sided p=0.022) with separation of Kaplan–Meier curves occurring around month 9. Potential disease modification from a pre-specified exploratory endpoint was observed as early as week 24 from baseline in the combination arm. VAF reduction =20% at week 24 occurred in 32.0% of patients receiving the selinexor combination versus 23.9% of patients receiving ruxolitinib alone and correlated with SVR35 response. Circulating peripheral blasts are a poor prognostic factor and potential marker of disease burden. A post-hoc analysis showed that more patients who received the selinexor combination and who had no detectable circulating peripheral blasts at baseline maintained no detectable blasts through the course of treatment compared to patients who received ruxolitinib alone. For patients with circulating peripheral blasts at baseline, more patients who received the selinexor combination had no detectable blasts through the course of treatment compared to patients who received ruxolitinib alone. The combination demonstrated a manageable safety and tolerability profile consistent with the known profile of selinexor and ruxolitinib individually. No new safety signals were observed. Treatment emergent adverse events (TEAEs) occurred in 99.1% of patients receiving the selinexor combination and in 97.4% of patients receiving ruxolitinib alone. The five most common all-grade TEAEs in the selinexor combination arm were thrombocytopenia (selinexor plus ruxolitinib arm: 59%; placebo plus ruxolitinib arm: 43%), anemia (57%; 58%), nausea (57%; 17%), constipation (32%; 36%) and neutropenia (27%; 9%) (n=234; n=116). The rate of grade 3+ TEAEs was 70% in the selinexor combination arm compared to 50% in the placebo plus ruxolitinib arm, and were primarily hematologic in nature. The percentage of patients treated with the combination who experienced TEAEs leading to death occurred in 0.9% of patients receiving the combination compared to 2.6% of patients receiving ruxolitinib alone. Confirmed leukemic transformation was 1.7% in each arm. SENTRY (XPORT-MF-034; NCT04562389) is a Phase 3 clinical trial evaluating a once-weekly dose of 60 mg of selinexor in combination with ruxolitinib compared to placebo plus ruxolitinib in JAKi-naïve myelofibrosis patients with platelet counts >100 x 109/L (N=353). Patients were randomized 2-to-1 to the selinexor arm. The co-primary endpoints for this trial are spleen volume reduction = 35% (SVR35) at week 24 and the average change in absolute total symptom score (Abs-TSS) over 24 weeks relative to baseline. XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor compound for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved and marketed by Karyopharm in the U.S. in multiple oncology indications, including: (i) in combination with VELCADE (bortezomib) and dexamethasone (XVd) in adult patients with multiple myeloma after at least one prior therapy; and (ii) in combination with dexamethasone in adult patients with heavily pre-treated multiple myeloma. XPOVIO (also known as NEXPOVIO in certain countries) has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including but not limited to the European Union, the United Kingdom, Mainland China, Taiwan, Hong Kong, Australia, South Korea, Singapore, Israel, and Canada. XPOVIO/NEXPOVIO is marketed in these respective ex-U.S. territories by Karyopharm's partners: Antengene, Menarini, Neopharm, and FORUS. Selinexor is also being investigated in several other mid- and late-stage clinical trials across multiple high unmet need cancer indications, including in myelofibrosis and endometrial cancer. XPOVIO (selinexor) is a prescription medicine approved: In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (XVd). In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody (Xd). Thrombocytopenia: Monitor platelet counts throughout treatment. Reported Earnings • May 16
First quarter 2026 earnings: EPS and revenues exceed analyst expectations First quarter 2026 results: US$1.02 loss per share (improved from US$2.77 loss in 1Q 2025). Revenue: US$35.1m (up 17% from 1Q 2025). Net loss: US$22.4m (loss narrowed 4.6% from 1Q 2025). Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) also surpassed analyst estimates by 17%. Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings. Announcement • May 15
Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full-Year of 2026 Karyopharm Therapeutics Inc. reaffirmed Earnings Guidance for the Full-Year of 2026. For the year, the company expects total revenue to be in the range of $130 million to $150 million. Announcement • May 07
Karyopharm Therapeutics Inc. to Report Q1, 2026 Results on May 14, 2026 Karyopharm Therapeutics Inc. announced that they will report Q1, 2026 results on May 14, 2026 Announcement • Apr 14
Karyopharm Therapeutics Inc., Annual General Meeting, May 21, 2026 Karyopharm Therapeutics Inc., Annual General Meeting, May 21, 2026. Price Target Changed • Mar 25
Price target decreased by 16% to US$12.83 Down from US$15.33, the current price target is an average from 6 analysts. New target price is 146% above last closing price of US$5.21. Stock is up 7.4% over the past year. The company is forecast to post a net loss per share of US$4.90 next year compared to a net loss per share of US$17.93 last year. Announcement • Mar 25
Karyopharm Therapeutics Inc. announced that it expects to receive $29.999661 million in funding from RA Capital Management, L.P. Karyopharm Therapeutics Inc. entered into a securities purchase agreement with new investor RA Capital Healthcare Fund, L.P., a fund managed by RA Capital Management, L.P. for issuance of 1,030,354 common shares at a price of $6.785 per share for gross proceeds of $6,990,951.89, and 3,391,164 pre-funded warrants to purchase up to 3,391,164 common shares at a purchase price of $6.7849 per pre-funded warrant for gross proceeds of $23,008,708.6236; for aggregate gross proceeds of $29,999,660.5136 on March 24, 2026. The company will also issue accompanying warrants to purchase 4,421,518 shares with an exercise price of $10 per share. The exercise price of the pre-funded warrants will be $0.0001 per share, and the pre-funded warrants will be immediately exercisable and will not expire. The closing of the private placement is subject to customary closing conditions and is expected to occur on or about March 26, 2026. The purchaser of the securities described herein represented, among other things, that it is an accredited investor, as such term is defined in Rule 501(a) of Regulation D under the Securities Act, and that it is acquiring such securities for investment purposes only and not with a view to any resale, distribution or other disposition of the Shares, the Pre-Funded Warrants and the Common Stock Warrants in violation of the United States federal securities laws. Announcement • Mar 24
Karyopharm Therapeutics Inc. Reports Topline Results From Phase 3 SENTRY Trial In Myelofibrosis Karyopharm Therapeutics Inc. reported topline results from its Phase 3 SENTRY trial, a randomized, double-blind, placebo-controlled trial of 60 mg selinexor in combination with ruxolitinib in frontline myelofibrosis (n=353). The trial met the first co-primary endpoint, demonstrating statistically significant improvement in spleen volume reduction of 35% or more (SVR35) for patients treated with the combination of selinexor plus ruxolitinib, with rapid, deep and sustained spleen volume reduction rates seen in the combination arm. The mean change in absolute total symptom score (Abs-TSS) at week 24 relative to baseline was comparable across the two arms with similar symptom improvement relative to baseline; the difference across the two arms was not statistically significant. The topline results suggest a promising signal in overall survival (OS) for the combination arm. Spleen Volume: 50% of patients who received the combination of selinexor plus ruxolitinib achieved a statistically significant improvement in SVR35 at week 24 compared to 28% of patients who received ruxolitinib alone (one-sided p. Symptoms: Similar symptom improvement from baseline was observed in patients who received the combination of selinexor plus ruxolitinib compared to ruxolitinib alone as measured by Abs-TSS at week 24. Patients who received the combination reported a 9.89 point improvement in Abs-TSS compared to a 10.86 point improvement in patients who received ruxolitinib alone. Overall Survival: Promising OS signal was observed in patients who received the combination of selinexor plus ruxolitinib compared to ruxolitinib alone with a hazard ratio of 0.43 (95% CI [0.19, 1.00] nominal one-sided p=0.0222). The Company intends to continue to follow OS to maturity to further evaluate this signal. Overall Survival Associated with SVR35: Post-hoc landmark analyses at weeks 12 and 24 suggest SVR35 may predict overall survival. Variant Allele Frequency (VAF) Reduction: Evidence of potential disease modification from a pre-specified exploratory endpoint was observed at week 24 from baseline in the combination arm as 32% of patients who received the combination achieved a =20% reduction in VAF for JAK2, MPL, and CALR compared to 24% of patients who received ruxolitinib alone (n=261). Other Secondary and Exploratory Endpoints: Across other secondary and exploratory endpoints of progression-free survival, hemoglobin stabilization, and bone marrow fibrosis improvement, no meaningful difference was observed between the trial arms as of the data cut-off of February 20, 2026. The Company intends to further evaluate these endpoints as they mature. Patients were randomized 2:1 to 60 mg of selinexor once weekly plus ruxolitinib or placebo plus ruxolitinib. The ruxolitinib dose was determined based on the patients' baseline platelet count per the drug's prescribing information. All data presented are as of the data cut-off of February 20, 2026. The combination demonstrated a manageable safety and tolerability profile consistent with the known profile of selinexor and ruxolitinib individually. No new safety signals were observed. The five most common all-grade treatment emergent adverse events (TEAEs) in the selinexor plus ruxolitinib arm were thrombocytopenia (selinexor plus ruxolitinib arm: 59%; placebo plus ruxolitinib arm: 43%), anemia (57%; 58%), nausea (57%; 17%), constipation (32%; 36%) and neutropenia (27%; 9%) (n=234; n=116). The rate of grade 3+ TEAEs was 70% in the selinexor plus ruxolitinib arm compared to 50% in the placebo plus ruxolitinib arm. The rate of TEAEs leading to treatment discontinuation was 15% in the selinexor plus ruxolitinib arm and 9% in the placebo plus ruxolitinib arm. The rate of confirmed leukemic transformations was the same across both arms of the trial at 1.7%. The Company will be meeting with the U.S. Food and Drug Administration (FDA) to discuss the totality of the data from the SENTRY trial and its supplemental new drug application (sNDA) filing plan. The Company plans to share additional data from the Phase 3 SENTRY trial at an upcoming medical meeting and expects to submit a manuscript to a peer-reviewed medical journal. The Company believes that potential inclusion in relevant compendia could occur in the second half of 2026. New Risk • Mar 14
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$233k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$75m free cash flow). Negative equity (-US$293m). Shareholders have been substantially diluted in the past year (118% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$119m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Significant insider selling over the past 3 months (US$233k sold). New Risk • Mar 08
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$196m Forecast net loss in 3 years: US$119m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$75m free cash flow). Negative equity (-US$293m). Shareholders have been substantially diluted in the past year (118% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$119m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Breakeven Date Change • Mar 02
Forecast to breakeven in 2028 The 7 analysts covering Karyopharm Therapeutics expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 17% per year to 2027. The company is expected to make a profit of US$25.0m in 2028. Average annual earnings growth of 61% is required to achieve expected profit on schedule. Major Estimate Revision • Feb 20
Consensus EPS estimates upgraded to US$5.07 loss The consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -US$5.78 to -US$5.07 per share. Revenue forecast unchanged from US$139.1m at last update. Biotechs industry in the US expected to see average net income decline 7.7% next year. Consensus price target of US$15.33 unchanged from last update. Share price rose 8.2% to US$9.67 over the past week. New Risk • Feb 15
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$196m Forecast net loss in 3 years: US$44m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$89m free cash flow). Negative equity (-US$293m). Shareholders have been substantially diluted in the past year (118% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$44m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Reported Earnings • Feb 13
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: US$17.93 loss per share (further deteriorated from US$9.41 loss in FY 2024). Revenue: US$146.1m (flat on FY 2024). Net loss: US$196.0m (loss widened 157% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 46%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings. New Risk • Feb 13
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$89m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$89m free cash flow). Negative equity (-US$293m). Shareholders have been substantially diluted in the past year (118% increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change). New Risk • Feb 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$269m). Shareholders have been substantially diluted in the past year (118% increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change). Breakeven Date Change • Feb 12
No longer forecast to breakeven The 7 analysts covering Karyopharm Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$40.5m in 2028. New consensus forecast suggests the company will make a loss of US$41.5m in 2028. Announcement • Feb 12
Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Full Year 2026 Karyopharm Therapeutics Inc. provided earnings guidance for the full year 2026. For the year, the Company expects total revenue to be in the range of $130 million to $150 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners. Announcement • Feb 05
Karyopharm Therapeutics Inc. to Report Q4, 2025 Results on Feb 12, 2026 Karyopharm Therapeutics Inc. announced that they will report Q4, 2025 results on Feb 12, 2026 Announcement • Jan 13
Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2025 Karyopharm Therapeutics Inc. provided earnings guidance for the fourth quarter and full year 2025. For the period, based on preliminary unaudited financial information, the Company expects total revenue, which includes license and royalty revenue from partners, to be approximately $33 million for the fourth quarter 2025.
For the full year, based on preliminary unaudited financial information, the Company expects total revenue, which includes license and royalty revenue from partners, to be approximately $145 million for the full year 2025. Reported Earnings • Nov 04
Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2025 results: US$3.82 loss per share. Revenue: US$44.0m (up 14% from 3Q 2024). Net loss: US$33.1m (loss widened 3.3% from 3Q 2024). Revenue exceeded analyst estimates by 3.9%. Earnings per share (EPS) missed analyst estimates by 8.4%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Announcement • Nov 04
Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full Year 2025 Karyopharm Therapeutics Inc. reaffirmed earnings guidance for the full year 2025. For the year, the company expects total revenue to be in the range of $140 million to $155 million. Breakeven Date Change • Nov 03
Forecast to breakeven in 2027 The 5 analysts covering Karyopharm Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$50.0m in 2027. Average annual earnings growth of 57% is required to achieve expected profit on schedule. Announcement • Oct 27
Karyopharm Therapeutics Inc. to Report Q3, 2025 Results on Nov 03, 2025 Karyopharm Therapeutics Inc. announced that they will report Q3, 2025 results on Nov 03, 2025 New Risk • Oct 26
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 92% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$239m). Earnings are forecast to decline by an average of 7.7% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (92% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$130m net loss next year). Share price has been volatile over the past 3 months (16% average weekly change). New Risk • Oct 16
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 7.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$239m). Earnings are forecast to decline by an average of 7.7% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable next year (US$130m net loss next year). Share price has been volatile over the past 3 months (17% average weekly change). Market cap is less than US$100m (US$51.6m market cap). Price Target Changed • Oct 13
Price target decreased by 11% to US$23.07 Down from US$25.92, the current price target is an average from 7 analysts. New target price is 311% above last closing price of US$5.62. Stock is down 56% over the past year. The company is forecast to post a net loss per share of US$12.00 next year compared to a net loss per share of US$9.41 last year. Major Estimate Revision • Oct 09
Consensus EPS estimates fall by 22% The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -US$9.88 to -US$12.04 per share. Revenue forecast unchanged at US$149.5m. Biotechs industry in the US expected to see average net income decline 11% next year. Consensus price target down from US$25.92 to US$24.42. Share price fell 7.5% to US$5.82 over the past week. New Risk • Sep 23
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$103m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-US$239m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$75m net loss in 3 years). Market cap is less than US$100m (US$50.7m market cap). Announcement • Sep 12
Karyopharm Therapeutics Inc. Announces Resignation of Mansoor Raza Mirza from the Board, Effective September 8, 2025 On September 5, 2025, Mansoor Raza Mirza, M.D., a member of the Board of Directors (the Board") of Karyopharm Therapeutics Inc. (the Company"), notified the Company of his resignation from the Board, effective as of September 8, 2025. Dr. Mirza's resignation is due to competing professional demands and not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. Dr. Mirza is also resigning from his position as Chief Oncologist at Copenhagen University National Medical Center, effective October 1, 2025, to focus his professional efforts on his new executive role in industry. In connection with Dr. Mirza's resignation, the consulting agreement between the Company and Mirza Consulting, an entity wholly-owned by Dr. Mirza, for consulting and advisory services provided to the Company by Dr. Mirza was terminated effective as of September 8, 2025. Announcement • Sep 11
Karyopharm Therapeutics Inc. Announces Completion of Enrollment in the Phase 3 Sentry Trial in Myelofibrosis Karyopharm Therapeutics Inc. announced the completion of enrollment in the Phase 3 SENTRY trial, which is evaluating selinexor in combination with ruxolitinib in JAKi-naïve myelofibrosis patients. The trial enrolled 353 patients and aims to assess the efficacy of this combination therapy, with top-line results anticipated in March 2026. The co-primary endpoints for this trial are spleen volume response rate = 35% (SVR35) at week 24 and the average change in absolute total symptom score (Abs-TSS) over 24 weeks relative to baseline. This trial is significant as it may lead to the first combination therapy approved for the treatment of myelofibrosis, depending on the outcome of the data. Major Estimate Revision • Aug 18
Consensus EPS estimates upgraded to US$9.83 loss The consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -US$12.80 to -US$9.83 per share. Revenue forecast steady at US$148.3m. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target down from US$29.25 to US$25.92. Share price rose 57% to US$5.92 over the past week. Reported Earnings • Aug 12
Second quarter 2025 earnings: EPS misses analyst expectations Second quarter 2025 results: US$4.32 loss per share (down from US$2.26 profit in 2Q 2024). Revenue: US$37.9m (down 11% from 2Q 2024). Net loss: US$37.3m (down 304% from profit in 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.2%. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Announcement • Aug 12
Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Full Year 2025 Karyopharm Therapeutics Inc. provided earnings guidance for the full year 2025. For the year, the company expects total revenue to be in the range of $140 million to $155 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners. Announcement • Aug 05
Karyopharm Therapeutics Inc. to Report Q2, 2025 Results on Aug 11, 2025 Karyopharm Therapeutics Inc. announced that they will report Q2, 2025 results on Aug 11, 2025 Major Estimate Revision • Jul 13
Consensus EPS estimates fall by 10% The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -US$11.61 to -US$12.80 per share. Revenue forecast unchanged at US$147.1m. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target of US$28.93 unchanged from last update. Share price rose 3.6% to US$4.55 over the past week. Reported Earnings • May 14
First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2025 results: US$2.77 loss per share (improved from US$4.13 loss in 1Q 2024). Revenue: US$30.0m (down 9.4% from 1Q 2024). Net loss: US$23.5m (loss narrowed 26% from 1Q 2024). Revenue missed analyst estimates by 15%. Earnings per share (EPS) exceeded analyst estimates by 35%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings. New Risk • May 13
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$128m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Negative equity (-US$186m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$133m net loss in 3 years). Significant insider selling over the past 3 months (US$170k sold). Market cap is less than US$100m (US$52.7m market cap). Price Target Changed • May 13
Price target decreased by 32% to US$33.07 Down from US$48.64, the current price target is an average from 7 analysts. New target price is 572% above last closing price of US$4.92. Stock is down 70% over the past year. The company is forecast to post a net loss per share of US$11.61 next year compared to a net loss per share of US$9.41 last year. Announcement • May 13
Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Year 2025 Karyopharm Therapeutics Inc. reaffirmed earnings guidance for the year 2025. Based on its current operating plans, the company expects the following for full year 2025: Total revenue to be in the range of $140 million to $155 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners. Announcement • May 09
Karyopharm Therapeutics Inc. to Report Q1, 2025 Results on May 12, 2025 Karyopharm Therapeutics Inc. announced that they will report Q1, 2025 results on May 12, 2025 Price Target Changed • Apr 15
Price target decreased by 21% to US$38.64 Down from US$48.93, the current price target is an average from 7 analysts. New target price is 807% above last closing price of US$4.26. Stock is down 74% over the past year. The company is forecast to post a net loss per share of US$14.45 next year compared to a net loss per share of US$9.41 last year. Announcement • Apr 15
Karyopharm Therapeutics Inc., Annual General Meeting, May 28, 2025 Karyopharm Therapeutics Inc., Annual General Meeting, May 28, 2025. New Risk • Mar 07
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$171k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$128m free cash flow). Negative equity (-US$186m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$133m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Significant insider selling over the past 3 months (US$171k sold). Market cap is less than US$100m (US$52.3m market cap). Recent Insider Transactions • Mar 07
President recently sold US$74k worth of stock On the 4th of March, Richard Paulson sold around 12k shares on-market at roughly US$6.29 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Richard has been a net seller over the last 12 months, reducing personal holdings by US$110k. Major Estimate Revision • Feb 26
Consensus EPS estimates fall by 24% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$161.3m to US$148.8m. Losses expected to increase from US$11.48 per share to US$14.21. Biotechs industry in the US expected to see average net income decline 10% next year. Consensus price target of US$58.08 unchanged from last update. Share price rose 9.2% to US$9.83 over the past week. Announcement • Feb 25
Karyopharm Announces 1-for-15 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Global Select Market Karyopharm Therapeutics Inc. announced that it will implement a 1-for-15 reverse stock split of the issued shares of the Company's common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on February 25, 2025. The Reverse Stock Split was approved by the Company's stockholders at the Company's Special Meeting of Stockholders held on January 30, 2025, with the final ratio subsequently determined by the Company's Board of Directors. One of the primary goals of the Reverse Stock Split is to increase the per-share market price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. Announcement • Feb 21
Karyopharm Therapeutics Inc. Auditor Raises 'Going Concern' Doubt Karyopharm Therapeutics Inc. filed its 10-K on Feb 19, 2025 for the period ending Dec 31, 2024. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern. Reported Earnings • Feb 19
Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2024 results: US$0.63 loss per share (improved from US$1.25 loss in FY 2023). Revenue: US$145.2m (flat on FY 2023). Net loss: US$76.4m (loss narrowed 47% from FY 2023). Revenue missed analyst estimates by 3.4%. Earnings per share (EPS) exceeded analyst estimates by 1.2%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings. Announcement • Feb 19
Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Full Year 2025 Karyopharm Therapeutics Inc. provided earnings guidance for the full year 2025. For the year, the company expects Total revenue to be in the range of $140 million to $155 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners. U.S. XPOVIO net product revenue to be in the range of $115 million to $130 million. Announcement • Feb 12
Karyopharm Therapeutics Inc. to Report Q4, 2024 Results on Feb 19, 2025 Karyopharm Therapeutics Inc. announced that they will report Q4, 2024 results Pre-Market on Feb 19, 2025 Major Estimate Revision • Jan 17
Consensus EPS estimates upgraded to US$0.64 loss, revenue downgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$152.9m to US$144.9m. 2024 losses expected to reduce from -US$0.732 to -US$0.637 per share. Biotechs industry in the US expected to see average net income decline 10% next year. Consensus price target of US$4.50 unchanged from last update. Share price fell 8.1% to US$0.66 over the past week. Announcement • Jan 15
Karyopharm Therapeutics Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2024 Karyopharm Therapeutics Inc. provided revenue guidance for the fourth quarter and full year 2024. For the quarter, the company expects total revenue to be approximately $30 million.
For the full year, the company expects revenue to be $145 million. Announcement • Dec 10
Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications Karyopharm Therapeutics Inc. announced the appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications. Most recently, Brendan served as Managing Director at Argot Partners where he advised biopharmaceutical companies on their investor relations and corporate communications programs. Previously, Brendan led investor relations for Tenet Healthcare and also served as Chief Financial Officer of Tenet's Massachusetts Market. Earlier in his career, he worked in the equity research department at Lehman Brothers and Barclays and also participated in a financial leadership training program at AT&T. Brendan earned an MBA from Harvard Business School and a B.S. in Finance from Rutgers University. 
